Coca-Cola's vitaminwater has taken a different approach with its rebrand. It's ditching the previous slightly pharmaceutical-looking identity in favour of bolder branding that aims to be fun rather ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The title of the panel, which was simply named’Can truth survive?’ was held at the Sir Harry Evans Investigative Journalism ...

WASHINGTON — President Donald Trump on Monday signed a sweeping executive order setting a 30-day deadline for drugmakers to electively lower the cost of prescription drugs in the U.S. or face new ...

While signs point to Pfizer being able to navigate pharmaceutical tariffs relatively well, there's still a financial risk. A potentially greater worry, though, is the White House's plan to implement ...

The Food and Drug Administration says that a prominent medical contrarian and critic of the drug industry will head its ...

Pfizer plans to explore other obesity treatments for testing. Pfizer is halting the development of its potential pill for treating obesity following an injury that happened during a clinical trial.

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. The company said it halted development of danuglipron, an oral ...

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

Matthew Herper covers medical innovation — both its promise and its perils. Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron ...